Table 2.

Commonly used initial therapy regimens and frequency

Regimen	2001–2005	2006–2010
VAD	2%	(1 patient)
Dexamethasone	45%	6%
Melphalan-Prednisone	21%	3%
Thalidomide-Dexamethasone	16%	3%
Other thalidomide-based regimen	0%	3%
Lenalidomide-Dexamethasone	11%	52%
Other lenalidomide-based regimen	0%	10%
Bortezomib-Dexamethasone	1%	7%
Other bortezomib-based regimen	0%	5%
VTD	0%	2%
VRD	0%	4%

Abbreviations: VAD Vincristine, Adriamycin and Dexamethasone; VTD Bortezomib (Velcade), Thalidomide and Dexamethasone; VRD Bortezomib (Velcade), Lenalidomide (Revlimid) and Dexamethasone